Currently out of the existing stock ratings of Joseph Munda, 14 are a BUY (77.78%), 4 are a HOLD (22.22%).

Joseph Munda

Work Performance Price Targets & Ratings Chart

Analyst Joseph Munda, currently employed at FIRST ANALYSIS, carries an average stock price target met ratio of 90% that have a potential upside of 20.19% achieved within 540 days.

Joseph Munda’s has documented 40 price targets and ratings displayed on 5 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on NEO, NeoGenomics at 28-Feb-2020.

Wall Street Analyst Joseph Munda

Analyst best performing recommendations are on ANIK (ANIKA THERAPEUTICS).
The best stock recommendation documented was for NEO (NEOGENOMICS) at 10/24/2018. The price target of $18 was fulfilled within 7 days with a profit of $3.59 (24.91%) receiving and performance score of 35.59.

Average potential price target upside

ANIK Anika Therapeutics LMAT LeMaitre Vascular NEO NeoGenomics ILMN Illumina SMED Sharps Compliance Corp

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

37

$11.3 (43.97%)

28

3 months 22 days ago

10/12 (83.33%)

$11.74 (46.48%)

110

Buy

32

$6.3 (24.51%)

61

1 years 22 days ago

1/3 (33.33%)

$11.99 (59.92%)

73

Hold

35

1 years 10 months 17 days ago

0/2 (0%)

$8.78 (33.49%)

Hold

46

$23.44 (103.90%)

46

2 years 9 months 13 days ago

0/2 (0%)

$5.44 (13.41%)

Buy

65

$39.3 (152.92%)

54

4 years 7 months 21 days ago

5/6 (83.33%)

$15.2 (30.52%)

21

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Joseph Munda?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?